N. Altorki

发表

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial.

M. Pasmantier, J. Port, R. Korst, 2003, The Journal of thoracic and cardiovascular surgery.

Celecoxib , a Select i ve Cyc lo-Oxygenase-2 Inhibi tor , Enhances the Response to Preoperat i ve Pacl i taxe l and Carboplat in in Early-Stage Non – Smal l-Cel l Lung Cancer

D. Yankelevitz, D. Libby, M. Pasmantier, 2003 .

Simultaneous pulmonary and renal malignancy.

D. Libby, N. Bander, N. Altorki, 1990, Chest.

Celecoxib, a selective COX-2 inhibitor, enhances the response to preoperative Paclitaxel/Carboplatin in early stage lung cancer

N. Altorki, 2003 .

Celecoxib, a S elective C yclo-Oxygenase- 2 I nhibitor, E nhances the R esponse t o P reoperative P aclitaxel a nd C arboplatin i n Early-Stage N on-Small-Cell L ung C ancer

K. Subbaramaiah, N. Altorki, 2003 .

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

D. Yankelevitz, D. Libby, M. Pasmantier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

A. Chella, H. Wakelee, C. Zhou, 2022, Journal of Thoracic Oncology.

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

H. Wakelee, C. Zhou, M. Das Thakur, 2021, Annals of Oncology.

PL03.06 Lobar or Sub-lobar Resection for Peripheral Clinical Stage IA = 2 cm Non-small Cell Lung Cancer (NSCLC): Results From an International Randomized Phase III Trial (CALGB 140503 [Alliance])

D. Wigle, D. Kozono, T. Stinchcombe, 2022, Journal of Thoracic Oncology.

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

A. Chella, H. Wakelee, C. Zhou, 2022, Annals of Oncology.

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

B. Nabet, H. Wakelee, J. Hamm, 2022, Immuno-Oncology and Technology.

Extent of resection and lymphadenectomy in early Barrett's cancer.

R. Korst, N. Altorki, 1997, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

A. Chella, H. Wakelee, E. Felip, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.